【摘要】 将 HBV 复制指标阳性的慢性乙型肝炎(慢乙肝)不同治疗的82侧随机分3组:单一药物组:应用抗乙型肝炎免疫核糖核酸;联合药物组:抗乙型肝炎免痰核糖核酸联合口服阿昔洛韦;对照组:肝泰乐。分别治疗慢乙肝井对血清 HBV 进行了对比观察。治疗结束后半年,联合药物组 HBsAg、HBeAg、抗HBc-IgM、HBV-DNA 阴转事分别为26.3%、52.6%、63.6%、64.4%及抗-HBs、抗-HBe 阳转率分别为10.5%、42.1%;单一药物组分别为16.7%、40.5%、48.1%、30.4%及4.8%、33.3%;对照组分别为4.8%、19.0%、0%、0%及0%、14.3%。结果表明:抗乙型肝炎免疫核糖核酸联合阿昔洛韦对清除和抑制HBV 有较明显的效果。更多还原

【Abstract】 82 chronic hepatitis B patients with HBV replicative marker positive are randomly divided in- to 3 groups,for which the simple drug is administered with anti-hepatitis B iRNA.The allied drug administered is both anti-hepatitis B iRNA and acyclovir and the control is administered with glucuronolactoni.In half year after the treatment,the experimental rasult shows that the negative alternative rates of HBsAg,HBeAg,anti-HBcIand HBV-DNA are 26.3%,52.6%, 63.6% and 64.4% respectively and the positive alternative rates of anti-HBs and anti-HBe are 10.5% and 42.1% respectively in the allied drug.While 16.7%,40.5%,48.1%,30.4%,4.8% and 33.3 %,respectively in the simple drug ;and 4.8 %,19.0 %,0,0 and 0,14.3 % respectively in the control.It is suggested that anti-hepatitis B iRNA combined with acyclovir has good effects on clearance and inhibition of HBV.更多还原